Dolosys GmbH, a Berlin, Germany-based start-up that has developed a pain monitor that can optimize pain therapy for sedated intensive care patients and patients with chronic pain, received a funding of undisclosed amount.
Backers included High-Tech Gründerfonds (HTGF) and m2f investment Ltd.
Led by Dr. Jan Baars, managing director, Dolosys GmbH is a medical technology business that focuses on the development and production of devices for the individualized measuring of pain and pain elimination. Its method leverages stimulated reflexes for the assessment of the analgesic effects of painkillers. Using the reflex bow, it measures non-invasively the effect of pain medication on the the spinal cord.
The company, which is a spin off the Charité – Universitätsmedizin Berlin.The company intends to use the funds to complete the development of its pain monitor and market it after its certification as a medical device in 2014.